Stockscreener 앱 받기
87.82
13.02%
-13.14
시간 외 거래:
85.63
-2.19
-2.49%
전일 마감가:
$100.96
열려 있는:
$102.52
하루 거래량:
161.56K
Relative Volume:
3.13
시가총액:
$541.85M
수익:
-
순이익/손실:
$-7.12M
주가수익비율:
-38.18
EPS:
-2.3
순현금흐름:
$-6.82M
1주 성능:
-11.64%
1개월 성능:
+104.71%
6개월 성능:
+175.56%
1년 성능:
+1,599%
1일 변동 폭
$86.26
$102.52
1주일 범위
$86.26
$105.00
52주 변동 폭
$4.50
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
명칭
Monopar Therapeutics Inc
전화
(847) 388-0349
주소
1000 SKOKIE BLVD SUITE 350, WILMETTE
MNPR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
87.82 | 622.92M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 개시 | BTIG Research | Buy |
| 2025-09-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-03 | 개시 | Raymond James | Strong Buy |
| 2025-08-26 | 재개 | H.C. Wainwright | Buy |
| 2025-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 개시 | Chardan Capital Markets | Buy |
| 2025-03-19 | 재개 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Piper Sandler | Overweight |
| 2024-10-11 | 개시 | Rodman & Renshaw | Buy |
| 2021-01-28 | 개시 | ROTH Capital | Buy |
모두보기
Monopar Therapeutics Inc 주식(MNPR)의 최신 뉴스
Institutional scanner results for Monopar Therapeutics Inc.2025 Momentum Check & High Win Rate Trade Alerts - newser.com
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential - TipRanks
What analysts say about Monopar Therapeutics Inc stockProtective Put Strategies & Low Risk Investment Trading - earlytimes.in
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
Real time social sentiment graph for Monopar Therapeutics Inc.Options Play & Community Driven Trade Alerts - newser.com
Raymond James Maintains Monopar Therapeutics (MNPR) Strong Buy Recommendation - Nasdaq
MNPR: Raymond James Raises Price Target to $142, Maintains Stron - GuruFocus
How to integrate Monopar Therapeutics Inc. into portfolio analysis toolsWatch List & Fast Gaining Stock Strategy Reports - newser.com
Historical volatility pattern of Monopar Therapeutics Inc. visualizedTrade Entry Summary & Entry Point Strategy Guides - newser.com
Will Monopar Therapeutics Inc. (1IY0) stock beat Nasdaq index returnsTrade Risk Summary & Long-Term Safe Investment Ideas - newser.com
Will Monopar Therapeutics Inc. stock recover faster than peersMarket Performance Report & Weekly Hot Stock Watchlists - newser.com
Risk adjusted return profile for Monopar Therapeutics Inc. analyzedJuly 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Can trapped investors hope for a rebound in Monopar Therapeutics Inc.Watch List & Fast Entry Momentum Alerts - newser.com
Is Monopar Therapeutics Inc. (1IY0) stock overpriced at current multiplesJuly 2025 Recap & Entry Point Confirmation Signals - newser.com
Is Monopar Therapeutics Inc. stock safe for conservative investorsPortfolio Gains Summary & Safe Entry Zone Identification - newser.com
Using portfolio simulators with Monopar Therapeutics Inc. includedJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
Analyzing Monopar Therapeutics Inc. with risk reward ratio chartsGlobal Markets & Community Shared Stock Ideas - newser.com
Can volume confirm reversal in Monopar Therapeutics Inc.July 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Oppenheimer Maintains Monopar Therapeutics (MNPR) Outperform Recommendation - Nasdaq
Oppenheimer Raises Price Target for Monopar Therapeutics (MNPR) - GuruFocus
Oppenheimer Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $115 - 富途牛牛
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $104 - 富途牛牛
HC Wainwright Has Optimistic Outlook of MNPR FY2027 Earnings - Defense World
What analysts say about Ayro Inc stockStop Loss Placement Tips & Exceptional Return Opportunities - earlytimes.in
Monopar Therapeutics (MNPR) Price Target Increased by 18.34% to 99.28 - Nasdaq
HC Wainwright & Co. Maintains Monopar Therapeutics (MNPR) Buy Recommendation - Nasdaq
Monopar Therapeutics Inc (MNPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Monopar Therapeutics Inc 주식 (MNPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
5.74%
자본화:
|
볼륨(24시간):